Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Comment by 90guppyon Nov 26, 2020 3:11pm
109 Views
Post# 31982708

RE:RE:VAXILBIO CORPORATE STRATEGY

RE:RE:VAXILBIO CORPORATE STRATEGYIt has been a month since the USAMRIID agreement was announced. by this tie the US Army scientists and VXL management has an idea if Corvax works in the genetically modified mice test. Based on the Tel Aviv test of Dr. Hagin, as early as 10 days Corvax was able to induce humoral response and developed antibodies and activated T-cells. So what does that tells you in relation to these management and insiders participating in the private placement. That's right, they have preliminary data, it may not be totally complete but they have an idea that Corvax may fully work that is why they bet now.


90guppy wrote: Better see SEDI filings, insiders are loading up

Charleyfarley wrote:
when public companies decide to advance their image or product in the best possible way for shareholders there will always be Frustration. I believe once the way forward with not only Covid19 but the testing currently going on with respect to Cancer and other Infectious Diseases that WILL show Face in the coming years , Shareholders will be Rewarded justly .




<< Previous
Bullboard Posts
Next >>